Liraglutide for Low-responders After Bariatric Surgery
- Sponsor
- Zuyderland Medisch Centrum
- Study ID
- NCT04643301
- Status
- Withdrawn
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Liraglutide Pen Injector — DRUGDaily subcutaneous injection of 3.0mg liraglutide (GLP-1 antagonist) for low-responders 3 months after bariatric surgery.
Study Details
To study the effect of Liraglutide (3.0 mg daily) on 9-month weight loss in low responders 3-months after bariatric surgery.
Key Dates
- First listed
- Nov 25, 2020
- Start date
- Dec 21, 2020
- Status verified
- Apr 2021
- Primary completion
- Dec 31, 2021
- Completion
- Dec 31, 2021
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Experimental: Adding Liraglutide to current treatment programAdding 3,0mg of Liraglutide to the current treatment program of low-responders 3 months after bariatric surgery.
Primary Outcome Measure
%TWL (%TWL) [ Time Frame: 6 months ]
Find similar trials
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Physical and Behavioral Traits of Overweight and Obese AdultsRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Bariatric Surgery RegistryEnrolling By Invitation · Virginia Commonwealth University · Richmond, Virginia
- Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular SystemRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia